SJ Medical
SJ Medical
As the healthcare landscape in Kyrgyzstan continues to modernize, the integration of Bioresorbable Vascular Scaffolds (BVS) represents a pivotal shift from traditional metal-based coronary intervention to advanced, physiologically restorative therapies. Hangzhou SJ Medical Co., Ltd. stands at the forefront of this transition, bridging the gap between high-end medical manufacturing and the specific clinical needs of the Kyrgyzstan market.
Kyrgyzstan’s cardiac centers, particularly those in Bishkek, are increasingly seeking "Vascular Restoration Therapy." Unlike traditional drug-eluting metal stents which leave a permanent cage in the artery, our bioresorbable solutions allow the vessel to regain its natural vasomotion—a critical requirement for long-term patient health. By partnering with local distributors, SJ Medical ensures that regional hospitals have access to world-class manufacturing standards, compliant with EAEU (Eurasian Economic Union) regulatory frameworks.
Hangzhou SJ Medical Co., Ltd. was established in 2015 and is dedicated to the research, development, manufacturing, and commercialization of vascular interventional medical devices. The company focuses on both cardiovascular and peripheral intervention fields, striving to provide safe, reliable, and innovative solutions for healthcare providers worldwide.
Over the years, SJ Medical has developed a comprehensive product portfolio covering key areas of vascular intervention. Its offerings span from various types of balloon catheters for coronary and peripheral applications to supporting access and diagnostic devices, as well as advanced stent systems. Through continuous innovation and strong R&D capabilities, the company has obtained multiple patents and international certifications.
The roadmap for BVS technology is clear: Complete Bioresorption within 12-24 months. We are investing heavily in polymer degradation kinetics to ensure our scaffolds provide optimal radial support during the critical healing phase, followed by total disappearance to prevent long-term inflammation risks.
For the Kyrgyzstan market, we prioritize:
A: Yes, our quality management system is ISO 13485 certified, which aligns with international standards frequently accepted by health authorities in CIS countries. We provide full documentation for local market entry.
A: Absolutely. We offer comprehensive educational support, ranging from clinical procedural guides to hands-on workshops for interventional cardiologists to ensure optimal patient outcomes.
A: We optimize our supply chain for regional partners, typically ensuring expedited shipping routes and localized inventory planning to reduce lead times significantly.
Let's discuss how our bioresorbable solutions can enhance your clinic's offerings.
